What Now After Brexit Delay? UK BioIndustry Association Asks
Executive Summary
Steve Bates, CEO of the UK BioIndustry Association, tries to untangle the increasingly chaotic Brexit process and establish how the various scenarios might pan out for the life sciences industry.
You may also be interested in...
Pharma Uncertainty Remains As UK Votes To Delay Brexit
UK members of parliament have ruled out a no-deal Brexit and voted to request a delay to the exit date, and they will vote again on the withdrawal deal next week. But all this just serves to exacerbate the uncertainty and frustration felt by businesses working in the pharmaceutical sector.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.